Psoriasis : types, triggers, and treatment strategies [E-Book]
Series: Dermatology--laboratory and clinical researchPublisher: New York : Nova Biomedical, [2013]Description: 1 online resourceContent type:- text
- computer
- online resource
- 9781626185852
- 1626185859
Contents:
PSORIASIS ; Library of Congress Cataloging-in-Publication Data ; Contents ; Preface ; Chapter 1 Keratinocytes in Psoriasis: Key Players in the Disease Process ; Abstract ; I. Skin Homeostasis and Regulation of Function; II. Psoriasis ; 1. Epidemiology ; 2. Clinical Features ; 3. Psoriasis and the Quality of Life; 4. Psoriasis-Associated Co-Morbidities ; 5. Histologic Features ; 6. Psoriasis Phenotypes ; Classification of Psoriasis According to the Clinical Phenotype ; I. Chronic Plaque Psoriasis ; II. Inverse Psoriasis ; III. Guttate Psoriasis ; IV. Erythrodermic Psoriasis.
V. Childhood Psoriasis VI. Pustular Psoriasis ; VII. Nail disease (Psoriatic Onychodystrophy) ; VIII. Psoriatic Arthritis (PsA) ; 7. Therapeutic Armamentarium ; i. Topical Therapy ; ii. Phototherapy ; Ultraviolet B Radiation (UVB) ; Acute ; Chronic ; iii. Systemic Therapy ; Etanercept is Discussed Below as A Representative of this Class of Biologic Therapies; 8. The Mystery of the Disease Origin ; 9. Emerging Drugs; The Controversial Role of DMF; Conclusion; References ; Chapter 2 Types, Triggers and Treatment Strategies of Psoriasis ; Abstract ; Introduction ; Triggering Factors.
Infections Drugs ; Cutaneous Traumas ; Stress and Psychosomatic Factors ; Alcohol ; Smoking ; Clinical Variants ; Psoriasis Vulgaris-Chronic Plaque Psoriasis ; Guttate Psoriasis ; Small Plaque Psoriasis ; Inverse Psoriasis; Seborrhoeic Psoriasis ; Scalp Psoriasis ; Palmoplantar (Non Pustular) Psoriasis ; Nail Psoriasis ; Mucous Membranes ; Pustular Psoriasis ; Erythrodermic Psoriasis ; Treatment; General Considerations ; Topical Treatments ; Corticosteroids; Vitamin D Analogues ; Tazarotene; Salicylic Acid ; Topical Calcineurin Inhibitors ; Anthralin; Coal Tar ; Phototherapy.
UVB Phototherapy Photochemotherapy; Systemic Oral Agents ; Methotrexate; Acitretin ; Cyclosporine ; Other Systemic Drugs; Biologics ; Alefacept ; Efalizumab ; Adalimumab; Etanercept ; Infliximab ; Ustekinumab ; Conclusion ; References ; Chapter 3 A New Strategy for the Treatment of Psoriasis: Keratin 17 (K17) -- Targeting Therapy ; Abstract ; Introduction ; 1. Keratin 17; 1.1. Expression and Location of Keratin 17 ; 1.2. Functions of Keratin 17; 1.3. Keratin 17 as an Immune Regulator ; 2. Keratin 17 and Psoriasis ; 2.1. Expression of K17 in Psoriasis.
2.2. K17 and Psoriasis-Associated Cytokines 2.2.1. Regulation of K17 Expression by IFN- ; 2.2.2. Regulation of K17 Expression by IL-17 and IL-22 ; 2.2.3. Signal-Regulated Kinase Pathway of K17 Expression ; 2.3. Impact of K17 on Psoriatic Autoreactive T Cells ; 2.3.1. Classic Antigens of Psoriatic T Cells in Different Types of Psoriasis; 2.3.2. Sequences in K17 Serving As Psoriatic T Cell-Epitopes ; 2.3. K17 and Autoimmune Positive Feedback Loops in Psoriasis ; 3. K17 and Treatment of Psoriasis ; 3.1. Treatments in Psoriasis ; 3.2. K17 in the Treatments of Psoriasis.
| Item type | Home library | Class number | URL | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|
| Electronic book | Stenhouse Library (Kingston Hospital) Online | Link to resource | Available |
Includes bibliographical references and index.
Description based on print version record.
PSORIASIS ; Library of Congress Cataloging-in-Publication Data ; Contents ; Preface ; Chapter 1 Keratinocytes in Psoriasis: Key Players in the Disease Process ; Abstract ; I. Skin Homeostasis and Regulation of Function; II. Psoriasis ; 1. Epidemiology ; 2. Clinical Features ; 3. Psoriasis and the Quality of Life; 4. Psoriasis-Associated Co-Morbidities ; 5. Histologic Features ; 6. Psoriasis Phenotypes ; Classification of Psoriasis According to the Clinical Phenotype ; I. Chronic Plaque Psoriasis ; II. Inverse Psoriasis ; III. Guttate Psoriasis ; IV. Erythrodermic Psoriasis.
V. Childhood Psoriasis VI. Pustular Psoriasis ; VII. Nail disease (Psoriatic Onychodystrophy) ; VIII. Psoriatic Arthritis (PsA) ; 7. Therapeutic Armamentarium ; i. Topical Therapy ; ii. Phototherapy ; Ultraviolet B Radiation (UVB) ; Acute ; Chronic ; iii. Systemic Therapy ; Etanercept is Discussed Below as A Representative of this Class of Biologic Therapies; 8. The Mystery of the Disease Origin ; 9. Emerging Drugs; The Controversial Role of DMF; Conclusion; References ; Chapter 2 Types, Triggers and Treatment Strategies of Psoriasis ; Abstract ; Introduction ; Triggering Factors.
Infections Drugs ; Cutaneous Traumas ; Stress and Psychosomatic Factors ; Alcohol ; Smoking ; Clinical Variants ; Psoriasis Vulgaris-Chronic Plaque Psoriasis ; Guttate Psoriasis ; Small Plaque Psoriasis ; Inverse Psoriasis; Seborrhoeic Psoriasis ; Scalp Psoriasis ; Palmoplantar (Non Pustular) Psoriasis ; Nail Psoriasis ; Mucous Membranes ; Pustular Psoriasis ; Erythrodermic Psoriasis ; Treatment; General Considerations ; Topical Treatments ; Corticosteroids; Vitamin D Analogues ; Tazarotene; Salicylic Acid ; Topical Calcineurin Inhibitors ; Anthralin; Coal Tar ; Phototherapy.
UVB Phototherapy Photochemotherapy; Systemic Oral Agents ; Methotrexate; Acitretin ; Cyclosporine ; Other Systemic Drugs; Biologics ; Alefacept ; Efalizumab ; Adalimumab; Etanercept ; Infliximab ; Ustekinumab ; Conclusion ; References ; Chapter 3 A New Strategy for the Treatment of Psoriasis: Keratin 17 (K17) -- Targeting Therapy ; Abstract ; Introduction ; 1. Keratin 17; 1.1. Expression and Location of Keratin 17 ; 1.2. Functions of Keratin 17; 1.3. Keratin 17 as an Immune Regulator ; 2. Keratin 17 and Psoriasis ; 2.1. Expression of K17 in Psoriasis.
2.2. K17 and Psoriasis-Associated Cytokines 2.2.1. Regulation of K17 Expression by IFN- ; 2.2.2. Regulation of K17 Expression by IL-17 and IL-22 ; 2.2.3. Signal-Regulated Kinase Pathway of K17 Expression ; 2.3. Impact of K17 on Psoriatic Autoreactive T Cells ; 2.3.1. Classic Antigens of Psoriatic T Cells in Different Types of Psoriasis; 2.3.2. Sequences in K17 Serving As Psoriatic T Cell-Epitopes ; 2.3. K17 and Autoimmune Positive Feedback Loops in Psoriasis ; 3. K17 and Treatment of Psoriasis ; 3.1. Treatments in Psoriasis ; 3.2. K17 in the Treatments of Psoriasis.
Master record variable field(s) change: 050
There are no comments on this title.
Log in to your account to post a comment.
London Health Libraries Consortium Privacy notice and Membership terms and conditions